[1] DUTCHER J D. The discovery and development of amphotericin B[J]. Dis Chest,1968,54(Suppl 1):296-298.
[2] HAMILTON-MILLER J M.Chemistry and biology of the polyene macrolide antibiotics[J]. Bacteriol Rev,1973,37(3):166-196.
[3] CAROLUS H, PIERSON S, LAGROU K, et al. Amphotericin B and other polyenes-discovery, clinical use, mode of action and drug resistance[J]. J Fungi (Basel), 2020, 6(4):321.
[4] LEWANDOWSKA A, SOUTAR C P, GREENWOOD A I, et al. Fungicidal amphotericin B sponges are assemblies of staggered asymmetric homodimers encasing large void volumes[J]. Nat Struct Mol Biol, 2021,28(12):972-981.
[5] ANDERSON T M,CLAY M C,CIOFFI A G,et al.Amphotericin forms an extramembranous and fungicidal sterol sponge[J]. Nat Chem Biol, 2014,10(5):400-406.
[6] MESA-ARANGO A C, SCORZONI L,ZARAGOZA O.It only takes one to do many jobs:amphotericin B as antifungal and immunomodulatory drug[J]. Front. Microbiol,2012,3:286.DOI:10.3389/fmicb.2012.00286.
[7] MARTINO R. Efficacy, safety and cost-effectiveness of amphotericin B lipid complex (ABLC):a review of the literature[J]. Curr Med Res Opin, 2004,20(4):485-504.
[8] GROLL A H,RIJNDERS B J A, WALSH T J,et al.Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin B[J]. Clin Infect Dis, 2019, 68(Suppl 4):S260-S274.
[9] LOO A S,MUHSIN S A, WALSH T J. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B[J]. Expert Opin Drug Saf, 2013,12(6):881-895.
[10] WANG X,MOHAMMAD I S,FAN L,et al. Delivery strategies of amphotericin B for invasive fungal infections[J]. Acta Pharm Sin B, 2021,11(8):2585-2604.
[11] ESPINEL-INGROFF A, TURNIDGE J. The role of epidemiological cutoff values (ECVs/ECOFFs) in antifungal susceptibility testing and interpretation for uncommon yeasts and moulds[J]. Rev Iberoam Micol, 2016,33(2):63-75.
[12] 朱利平,管向东,黄晓军,等.中国成人念珠菌病诊断与治疗专家共识[J].中国医学前沿杂志(电子版),2020,12(1):35-50.
[13] DEMIR K K, BUTLER-LAPORTE G, DEL CORPO O, et al. Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis:A systematic review and network meta-analysis[J]. Mycoses, 2021,64(9):1098-1110.
[14] 唐晓丹,李光辉.2016年美国感染病学会曲霉病诊断处理实践指南[J].中国感染与化疗杂志,2017,17(4):456-462.
[15] DUCKWALL M J, GALES M A, GALES B J. Inhaled amphotericin B as aspergillosis prophylaxis in hematologic disease:an update[J]. Microbiol Insights, 2019,12:1178636119869937. DOI:10.1177/1178636119869937.
[16] 郭海健,彭春玲,刘小霞.两性霉素B雾化吸入加局部灌注联合伏立康唑治疗侵袭性肺部真菌感染研究[J].实用临床医药杂志,2020,24(14):41-44.
[17] GODET C, COUTURAUD F, MARCHAND-ADAM S,et al. Nebulised liposomal-amphotericin-B as maintenance therapy in ABPA:a randomised, multicentre, trial[J]. Eur Respir J, 2021:2102218.DOI:10.1183/13993003.02218-2021.
[18] AMBATI S,FERARRO A R,KANG S E,et al.Dectin-1-targeted antifungal liposomes exhibit enhanced efficacy[J]. mSphere, 2019,4(1):e00025-19.
[19] AMBATI S,ELLIS E C,PHAM T,et al.Antifungal liposomes directed by dectin-2 offer a promising therapeutic option for pulmonary aspergillosis[J]. mBio, 2021,12(1):e00030-21.
[20] WHO. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents and children:supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. https://www.ncbi.nlm.nih.gov/books/NBK531449/pdf/Bookshelf_NBK531449.pdf.Geneva:World Health Organization,2018.
[21] JARVIS J N, LAWRENCE D S, MEYA D B, et al. Single-dose liposomal amphotericin B treatment for cryptococcal meningitis[J]. N Engl J Med, 2022,386(12):1109-1120.
[22] 刘正印,王贵强,朱利平,等.隐球菌性脑膜炎诊治专家共识[J].中华内科杂志,2018,57(5):317-323.
[23] YANG M,CHENG L,DAI Q,et al.A novel cryptococcal meningitis therapy:The combination of amphotericin B and posaconazole promotes the distribution of amphotericin B in the brain tissue[J]. Biomed Res Int, 2020,2020:8878158.DOI:10.1155/2020/887815.
[24] CORNELY O A,ALASTRUEY-IZQUIERDO A,ARENZ D,et al.Global guideline for the diagnosis and management of mucormycosis:an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium[J]. Lancet Infect Dis, 2019,19(12):e405-e421.
[25] AZAR M M, LOYD J L,RELICH R F, et al.Current concepts in the epidemiology, diagnosis, and management of histoplasmosis syndromes[J]. Semin Respir Crit Care Med, 2020,41(1):13-30.
[26] JOHNSON P C,WHEAT L J,CLOUD G A,et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS[J]. Ann Intern Med, 2002,137(2):105-109.
[27] WHEAT L J,FREIFELD A G,KLEIMAN M B,et al.Clinical practice guidelines for the management of patients with histoplasmosis:2007 update by the Infectious Diseases Society of America[J]. Clin Infect Dis, 2007,45(7):807-825.
[28] 《中华传染病杂志》编辑委员会.中国利什曼原虫感染诊断和治疗专家共识[J].中华传染病杂志,2017,35(9):513-518.
[29] ROMERO G A S, COSTA D L, COSTA C H N, et al. Efficacy and safety of available treatments for visceral leishmaniasis in Brazil:A multicenter, randomized, open label trial[J]. PLoS Negl Trop Dis, 2017,11(6):e0005706.
[30] GOSWAMI P,HIYA B C,KUMAR V,et al.Comparison of efficacy of two different concentrations of intralesional amphotericin B in the treatment of cutaneous leishmaniasis; a randomized controlled trial[J]. Indian Dermatol Online J, 2019,10(6):627-631.
[31] LANZA J S,POMEL S,LOISEAU P M,et al. Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases[J]. Expert Opin Drug Deliv, 2019,16(10):1063-1079.
[32] JOHANSEN H K, GØTZSCHE P C.Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia[J]. Cochrane Database Syst Rev, 2014,2014(9):CD000969.
[33] YOSHIDA M, TAMURA K, MASAOKA T,et al. A real-world prospective observational study on the efficacy and safety of liposomal amphotericin B in 426 patients with persistent neutropenia and fever[J]. J Infect Chemother,2021,27(2):277-283.
[34] MIYAO K, SAWA M, KURATA M,et al. A multicenter phase 2 study of empirical low-dose liposomal amphotericin B in patients with refractory febrile neutropenia[J]. Int J Hematol, 2017,105(1):79-86.
[35] AKASHIMA Y,YOSHIDA C,KUBONISHI S,et al.Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropaenia and persistent fever[J]. Mycoses, 2020,63(8):794-801.
[36] HAN Y,LIU Y,MA X, et al.Antibiotics armed neutrophils as a potential therapy for brain fungal infection caused by chemotherapy-induced neutropenia[J]. Biomaterials, 2021,274:120849.DOI:10.1016/j.biomaterials.2021.120849.
[37] LE T, KINH N V, CUC N T K, et al. A trial of itraconazole or amphotericin B for HIV-associated talaromycosis[J]. N Engl J Med, 2017,376(24):2329-2340.
[38] ZHANG J,WU X,LI M,et al.Synergistic effect of terbinafine and amphotericin B in killing Fonsecaea nubica in vitro and in vivo[J]. Rev Inst Med Trop Sao Paulo, 2019,61:e31.DOI:10.1590/S1678-9946201961031. |
